



Cancer Trials New Zealand Annual Scientific Meeting



Thursday 24th October 2019

The Loft, Harbourside Function Centre, Wellington

9.30 – 10.00 TEA/COFFEE & REGISTRATION

10.00 – 10.10	Welcome	Michael Findlay & Nicky Lawrence
10.10 – 10.30	CTNZ update	Sarah Bengé

MORNING SESSIONS

SESSION 1: TITLE TBC

Chairs: Kate Clark & Michael Findlay

10.30 – 10.55	Kia whakakōtahitia a te Mātai Mate-Pukupuku i roto i te Ao Māori – He Tono mō te Rangahau Integrating Oncology into Te Ao Māori: a Research Proposal	George Laking
10.55 – 11.10	<i>Discussion</i>	
11.10 – 11.35	How do we measure the value of new medicines in the real world – access, efficacy and equity?	Matthew Strother
11.35 – 11.50	<i>Discussion</i>	

SESSION 2: CONSUMER REPRESENTATIVES

Chair: Sarah Bengé

11.50 – 12.00	Introduction to CTNZ's Consumer Representatives	Lou Clement
12.00 – 12.15	Consumer Representatives: How can we best assist?	Emma Crowley
12.15 – 12.30	Consumer Representative Involvement in Grant Application Review - OSCAR and RENO NZ studies (2020 HRC Project EOIs)	Lizzie Martin

12.30 – 1.30 LUNCH

AFTERNOON SESSIONS

SESSION 3: CTNZ's IT SYSTEMS Chair: TBC

1.15 – 1.30	Overview of Data Management at CTNZ	Lusiane Belaus
1.30 - 1.45	Managing clinical research using EDGE – how CTNZ tracks, manages and monitors its studies from start to finish	Rebecca Hu

SESSION 4: DISSEMINATION OF OVERSEAS EXPERIENCE Chair: Nicky Lawrence

1.45 – 2.15	A Cook's Tour of Clinical Fellowship at Peter MacCallum Cancer Centre (VCCC), Melbourne	Annie Wong
2.15 – 2.45	Translational cancer research; lessons from the American Association for Cancer Research workshop	Kathryn Burns

2.45 – 3.00 AFTERNOON TEA

SESSION 5: ONGOING STUDIES Chair: Anne O'Donnell

3.00 – 3.15	YWWPABC - Younger Women's Wellness Programme after Breast Cancer <i>(Funder: HRC Feasibility)</i>	Bobbi Laing
3.15 – 3.30	PantoCIN - Effectiveness of pantoprazole against delayed chemotherapy-induced nausea and vomiting in breast cancer patients <i>(Funders: Breast Cancer Foundation NZ and Breast Cancer Trials)</i>	Richard Isaacs
3.30 – 3.45	Thymine2 - Ability of the thymine loading test to categorise GI or breast cancer patients intolerant to 5FU treatment. <i>(Funder: HRC)</i>	Nuala Helsby
3.45 – 4.00	KISS - Dasatinib followed by imatinib in newly diagnosed, previously untreated patients with chronic phase CML. <i>(Funder: Leukaemia and Blood Foundation)</i>	Peter Browett
4.00 – 4.15	INSIGHT-FULL - a survey to explore clinical trial availability and accrual in New Zealand <i>(Funder: CTNZ core funds)</i>	Nicky Lawrence
4.15 – 4.30	PROSPER - Profiling of oncology patients as part of clinical care and research <i>(Funder: Li Family Trust - UoA)</i>	Cristin Print
4.30—4.45	PIPER - update	Kate Gorton
4.45 – 5.00	Wrap up and Close	Nicky Lawrence

END OF MEETING